Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Adaptive Biotechnologies (ADPT) is significantly outperforming its medical sector peers, with a year-to-date gain of 74.5% compared to the sector's average loss of 2.3%; the company holds a Zacks Rank #2 (Buy), driven by a 5.5% increase in its full-year earnings consensus estimate over the past 90 days. CVS Health (CVS) is also outperforming the sector with a 43.2% year-to-date return and a 4.1% increase in its current year EPS estimate, also holding a Zacks Rank #2 (Buy).

Analysis

Adaptive Biotechnologies (ADPT) has demonstrated significant outperformance within the Medical sector this year, registering a year-to-date gain of approximately 74.5%, starkly contrasting with the Medical sector's average loss of 2.3%. This performance is supported by a Zacks Rank of #2 (Buy), underpinned by a 5.5% upward revision in its full-year earnings consensus estimate over the past 90 days, signaling improving analyst sentiment and a positive earnings outlook. The Medical sector itself, comprising 998 stocks, holds a Zacks Sector Rank of #6, indicating a relatively weaker overall standing. ADPT, a member of the Medical - Biomedical and Genetics industry (Zacks Industry Rank #80), is also outperforming its specific industry, which has seen an average loss of 0.2% year-to-date. Similarly, CVS Health (CVS) has outperformed the Medical sector with a year-to-date return of 43.2% and also holds a Zacks Rank #2 (Buy), following a 4.1% increase in its consensus EPS estimate for the current year over the past three months. CVS Health belongs to the Medical Services industry (Zacks Industry Rank #69), which has experienced a 0.9% decline year-to-date, highlighting CVS's relative strength. The positive earnings estimate revisions for both ADPT and CVS suggest these companies are on a trajectory that, according to the Zacks Rank methodology, often precedes market outperformance over the next one to three months.

Key Decisions for Investors

• Investors should consider Adaptive Biotechnologies for its robust year-to-date performance and positive earnings estimate revisions, which suggest potential for continued momentum despite the broader Medical sector's underperformance.
• CVS Health also warrants attention as a strong performer within the Medical sector, with its significant YTD gains and favorable EPS estimate trends indicating a solid operational outlook.
• Given the Zacks Rank #2 (Buy) for both ADPT and CVS, which emphasizes positive earnings estimate trends, these stocks may present opportunities for outperformance in the near term (one to three months), meriting close monitoring against the backdrop of their respective industry and sector trends.